NPS Pharmaceuticals, Inc. Joins the Hypoparathyroidism Association in Recognition of World Hypoparathyroidism Awareness Day
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced its support for World Hypoparathyroidism Awareness Day, which encourages patients, physicians, and caregivers to increase awareness of the disorder and the need for more education, improved diagnosis, and new, long-term treatment options. Hypoparathyroidism is a rare disorder in which the body produces insufficient levels of parathyroid hormone, the principal regulator of calcium and phosphorus.
Help employers find you! Check out all the jobs and post your resume.
BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced its support for World Hypoparathyroidism Awareness Day, which encourages patients, physicians, and caregivers to increase awareness of the disorder and the need for more education, improved diagnosis, and new, long-term treatment options. Hypoparathyroidism is a rare disorder in which the body produces insufficient levels of parathyroid hormone, the principal regulator of calcium and phosphorus.
Help employers find you! Check out all the jobs and post your resume.